Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT03501576
- Status
- Recruiting
Conditions
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Inactivated Influenza Vaccine — BIOLOGICALGiven seasonal inactivated influenza vaccine IM
Study Details
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.
Key Dates
- Start date
- Apr 6, 2018
- Status verified
- Feb 2026
- Primary completion
- May 26, 2026
- Completion
- May 26, 2026
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: Inactivated Influenza VaccinePatients will be vaccinated with an FDA approved seasonal inactivated influenza vaccine
- Arm: Qualifying subjects to receive a SARS-CoV2 vaccine.Patients receive a SARS-CoV2 vaccine.
- Arm: Clinical Group Receiving SARS-CoV2 Booster VaccinesPatients receive a SARS-CoV2 vaccine.
Primary Outcome Measure
Cohort 1: Percentage of subjects achieving seroprotection, defined as the percentage of subjects with a post-vaccination HI titer > 1:40 [ Time Frame: Up to 180 days after immunization ]
Central Contacts
- Andres Chang, MD, PhD404-778-3942
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | Andres Chang, MD, PhD (PRINCIPAL_INVESTIGATOR) |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 |
Find similar trials in Atlanta, GA
By condition
By specialty
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular LymphomaPHASE2 · Not Yet Recruiting · XEME Biopharma Inc. · Newnan, Georgia
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE1 · Recruiting · Imugene Limited · Gilbert, Arizona